According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “
Several other equities analysts have also weighed in on the stock. BidaskClub lowered shares of OraSure Technologies from a buy rating to a hold rating in a report on Tuesday, November 12th. Canaccord Genuity reiterated a hold rating and set a $8.00 price objective on shares of OraSure Technologies in a report on Monday, November 11th. Finally, ValuEngine upgraded shares of OraSure Technologies from a sell rating to a hold rating in a report on Wednesday, October 2nd.
Shares of NASDAQ OSUR traded down $0.16 during trading on Friday, hitting $7.68. 47,877 shares of the company traded hands, compared to its average volume of 670,578. The business’s fifty day moving average is $8.12 and its 200 day moving average is $8.18. OraSure Technologies has a fifty-two week low of $6.35 and a fifty-two week high of $13.88. The firm has a market capitalization of $493.81 million, a price-to-earnings ratio of 15.60, a P/E/G ratio of 4.57 and a beta of 1.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.85 and a current ratio of 7.72.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.18. OraSure Technologies had a net margin of 15.80% and a return on equity of 5.93%. The firm had revenue of $35.99 million for the quarter, compared to analyst estimates of $38.62 million. During the same quarter in the prior year, the business earned $0.13 earnings per share. The business’s quarterly revenue was down 21.6% compared to the same quarter last year. On average, analysts predict that OraSure Technologies will post 0.14 EPS for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of OSUR. Acadian Asset Management LLC acquired a new stake in shares of OraSure Technologies in the 2nd quarter worth about $25,000. BSW Wealth Partners acquired a new stake in shares of OraSure Technologies in the 2nd quarter worth about $29,000. Panagora Asset Management Inc. raised its holdings in shares of OraSure Technologies by 34.3% in the 2nd quarter. Panagora Asset Management Inc. now owns 9,851 shares of the medical instruments supplier’s stock worth $91,000 after acquiring an additional 2,514 shares during the last quarter. Quantamental Technologies LLC raised its holdings in shares of OraSure Technologies by 107.0% in the 2nd quarter. Quantamental Technologies LLC now owns 10,311 shares of the medical instruments supplier’s stock worth $96,000 after acquiring an additional 5,330 shares during the last quarter. Finally, Pacer Advisors Inc. acquired a new stake in shares of OraSure Technologies in the 2nd quarter worth about $104,000. Institutional investors own 96.01% of the company’s stock.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Featured Story: What causes a stock to be most active?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.